Brief: Exact Therapeutics Announces Final Positive Data From Phase 1 Trial
20/05/2025 07:32
May 20 (Reuters) - Exact Therapeutics AS EXTX.OL: ANNOUNCES FINAL POSITIVE DATA FROM PHASE 1 TRIAL ACT-TREATED TUMORS SHOW GREATER REDUCTION THAN CONTROL TUMORS PS101 SAFE AND WELL TOLERATED WITH CHEMOTHERAPY ACT TREATMENT WITH PS101 SHOWS DOSE-RESPONSE RELATIONSHIP Source text: ID:nObi5FmpBa Further company coverage: EXTX.OL (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Exact Therapeutics AS
See all newsBrief: EXACT Therapeutics AS Gets Positive Safety Review For 60 Μl/Kg Dose In Phase 2 ENACT Trial
Brief: Exact Therapeutics Introduces New Long-Term Incentive Program
Brief: Exact Therapeutics H1 Operating Loss Widens To NOK 45.9 Million
Brief: Exact Therapeutics Announces Grant Of Core Patent In U.S.
Brief: Exact Therapeutics Announces Final Positive Data From Phase 1 Trial